Kornimate/medical-research-clean huggingface dataset:
the effect of therapeutic climbing on muscle strength, tone and balance in hemiplegic children

Conditions: Hemiplegia and Hemiparesis

Summary: the goal of this randomised controlled trial is to learn about the effect of therapeutic climbing in hemiplegic children. the main questions it aims to answer are: does climbing affect muscle strength and tone? what is its connection between normative data drawn from healthy children? how can it affect balance? participants (children) will be asked to complete an series of movements used in sports climbing, such as inside-flag, back-flag and horizontal traverse, while hanging on an in-door climbing wall.


Eligibility criteria:
inclusion criteria: * children from 4 to 16 years old * children with hemiplegia * evaluated as level 1 on gmfcs exclusion criteria: * botulinum toxin injection in last 6 months * surgery in the last 1 year (myofascial lengthening etc.) * children with poor cognitive skills (not following instructions etc.)

Keywords: therapeutic climbing hemiplegia children muscle strength balance
mint i multi- institutional neo-adjuvant therapy mammaprint project i

Conditions: Breast Cancer

Summary: genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. this study is designed to test the ability of mammaprint® in combination with targetprint®, blueprint®, and theraprint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (labc).

patients with suspected primary breast cancer on mammography and clinical examination will be assessed for eligibility by having a needle core biopsy to confirm invasive carcinoma. a fresh unfixed tumor specimen, incisional or core biopsy will be sent to agendia to determine the mammaprint risk profile, the blueprint molecular subtyping profile, the targetprint er, pr and her2 single gene readout, the 56-genetheraprint research gene panel and the additional genes as measured on the whole genome (44k) array. surgical protocol: 1. determination of nodal status: * for clinically node-negative patients: axillary ultra sound, followed by sentinel lymph node (sln) biopsy * for clinically node-positive patients: ultra sound-guided fine needle aspirate (fna), followed by core biopsy 2. neo-adjuvant chemotherapy 3. definitive surgery: * for node-positive patients: lumpectomy, repeat sln biopsy, axillary lymph node dissection (alnd) * for node-negative patients: lumpectomy, repeat sln biopsy (optional), no alnd response will be measured by pathological complete response (pcr) and by centrally assessed residual cancer burden (rcb).

Eligibility criteria:
inclusion criteria: * women with histologically proven invasive breast cancer and no distant metastases and; * lymphnode negative and a clinical tumor classification of t2 (≥3.5cm)-t4 or with 1-3 positive lymph nodes and a clinical tumor classification of t2-t4 dcis or lcis are allowed in addition to invasive cancer at t2 or t3 level. * age ≥ 18 years. * at least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or mri images to define specific size and validate complete pathologic response. * adequate bone marrow reserves (neutrophil count \>1.5 x109 /l and platelet count \>100 x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and hepatic function (alat, asat ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5 x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal). * signed informed consent of the patient exclusion criteria: * any patient with confirmed metastatic disease. patients with inflammatory breast cancer. * tumor sample shipped to agendia with ≤ 30% tumor cells or that fails quality assurance or quality control criteria. * patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer. * any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease.

Keywords: breast cancer neo adjuvant therapy
the strategy of implementation of the eras protocol after esophageal surgery

Conditions: ERAS; Esophageal Diseases

Summary: application of the perioperative enhanced recovery protocol has allowed to carry out esophagectomy to the patients with severe comorbidities and has led reducing the risks of severe postoperative complications.

the clinical trial included the parients who participated in the protocol eras since 2011, who uderwent esophagectomy with simultaneous reconstruction. the parients had benign or malignant esophageal diseases. the eras protocol consisted of components of perioperative recovery. the number of patients until now has reached 400 patients. during trial there was modifications of aspects of eras protocol such as a rejection of nasogastric tube or cervical drenage. the role of multidisplinary team is the main success of the result of the implemented eras protocol.

Eligibility criteria:
inclusion criteria: * all patients with esophageal diseases exclusion criteria: * before 18 years old * who do not need surgery as a treatment * who not underwent simultaneous recontruction
comparison between uterine artery doppler and placental vascular indices in prediction of preeclampsia

Conditions: Pre-Eclampsia

Summary: • preeclampsia is a multisystem disorder that can cause considerable maternal and fetal morbidity and mortality. late preeclampsia (with delivery \>34 weeks) is more frequent and less serious than early preeclampsia (with delivery \<34 weeks). poor early placentation has been especially associated with early disease. early identification of women at risk of preeclampsia is currently a crucial aim of antenatal care since they may benefit from prophylactic treatment and increased surveillance.

* the introduction of three-dimensional (3d) ultrasound techniques, with the option of calculating placental volume and measuring vascular indices, has created an excellent opportunity to study early changes in the uteroplacental circulation space, which includes the maternal spiral arteries and the intervillous space. this technology may allow a more direct evaluation of the abnormal placentation process thought to herald the development of preeclampsia. * the aim of this study was to assess the usefulness of placental volume and 3d vascular indices as reliable predictors of early preeclampsia in comparison to uterine artery doppler

Eligibility criteria:
inclusion criteria: * a. control group: pregnant women: 1. age between 18-35 years 2. parity: primigravidas and multiparas. 3. have no history of preeclampsia or eclampsia. 4. have no history of chronic hypertension. 5. not diabetic. 6. not have antiphospholipid syndrome. 7. not have autoimmune disease such as sle. b. high risk group: pregnant women with: 1. history of preeclampsia -eclapmsia 2. chronic hypertension 3. diabetic 4. antiphospholipid syndrome. 5. autoimmune syndrome such as sle. exclusion criteria: * • smoking * dichorionic placentae * fetal anomaly * uterine fibroid at the site of placental implantation * subchorionic hematoma
non-invasive detection of driveline infections in patients with a left ventricular assist device

Conditions: LVAD (Left Ventricular Assist Device) Driveline Infection

Summary: the aim of this single center observational study is to determine the feasibility of using non-invasive imaging methods, including smartphone photography and infrared thermography, for detecting of dlis in lvad patients in terms of severity, extent and natural healing process.

observational data of the driveline exit of lvad patients will be collected during a follow-up period of 26 weeks. two non-invasive imaging methods will be used. smartphone photos will be taken weekly by the patient during routine wound care in the home environment. in case the patient is admitted for driveline infection, infrared thermographic (irt) photography will be used to make thermographic photos of the driveline exit and the abdominal area of the subcutaneous driveline. furthermore, existing smartphone images and diagnostic data regarding prior dli status will be obtained from the electronic patient records. imaging data will additionally be retrospectively analyzed using artificial intelligence (ai) and machine learning for the development of a predictive ai model.

Eligibility criteria:
inclusion criteria: patients age 16 years or older, implanted with an lvad, followed at erasmus mc, with access to a smartphone with a built-in camera, who have signed an informed consent for data collection. exclusion criteria: known cognitive problems, like dementia etc., non-cardiac disease or cardiac diseases resulting in a life expectancy less than 1 years, inability to read or sign the informed consent form.

Keywords: infection lvad detection monitoring driveline infection imaging non-invasive
family planning counseling for women with chronic medical conditions in an inpatient setting

Conditions: Chronic Disease

Summary: women with chronic medical conditions have been found in multiple studies to use birth control less often compared to women without chronic medical conditions. the investigators hypothesized that approaching women with chronic medical conditions who were admitted to the hospital and having a bedside conversation about pregnancy intention and counseling regarding birth control usage along with offering to start birth control before discharge would increase the use of birth control in this population. as a separate intervention, the investigators hypothesized that having a brief conversation with the participants and then giving them a flyer that recommended talking with their doctor about birth control could also increase the use of birth control in this population.


Eligibility criteria:
inclusion criteria: * currently admitted to the hospital * has one or more qualifying chronic medication conditions listed in their chart (hypertension, obesity with bmi\>35, diabetes, current or history of breast cancer, rheumatoid arthritis, sickle cell disease, or lupus) exclusion criteria: * currently pregnant * using surgical or non-surgical contraception * immediately post-partum or admitted to the gynecology service * non-english speaking * non-verbal or too ill to consent

Keywords: contraception access to contraception health inequities acute care setting inpatient
a study to evaluate the safety, tolerability and efficacy of mhv370 in participants with sjogren's syndrome (sjs) or mixed connective tissue disease (mctd)

Conditions: Sjogren Syndrome; Mixed Connective Tissue Disease

Summary: this study was a basket trial designed to establish safety, tolerability and efficacy of mhv370 in sjögren's syndrome (sjs) and mixed connective tissue disease (mctd).

this was a randomized, participant and investigator blinded, placebo-controlled, multi center parallel group basket study to evaluate the safety, tolerability and efficacy of mhv370 in participants with sjögren's syndrome (sjs) or with mixed connective tissue disease (mctd). participants first underwent a screening period of up to 6 weeks, followed by a treatment duration of 24 weeks and a follow-up period of 4 weeks. total study duration for each participant was up to 34 weeks. participants with sjs were randomized in a 1:1 ratio to mhv370 or placebo and participants with mctd were randomized in a 1:1 ratio to mhv370 or placebo.

Eligibility criteria:
inclusion criteria: sjs and mctd: • fully vaccinated with any locally approved covid-19 vaccination including booster vaccinations if required by local guidelines sjs: * unstimulated whole salivary flow rate of \> 0 ml/min at screening * classification of sjögren's syndrome according to the 2016 acr/eular criteria at screening * screening essdai (based on weighted score) ≥ 5 from 8 defined domains (biologic, hematologic, articular, cutaneous, glandular, lymphadenopathy, renal, constitutional). mctd: * diagnosis of mctd based on criteria like a) raynaud's phenomenon b) at least two of the four following signs: i) synovitis, ii) myositis, iii) swollen fingers and vi) interstitial lung disease * patients with overlap syndromes, i.e. patients meeting diagnostic criteria for systemic autoimmune disease other than mctd may be included unless they have major organ involvement as judged by the investigator exclusion criteria: sjs and mctd: * prior use of b-cell depleting therapy within 6 months of baseline. for participants who received b-cell depleting therapy within 6 -12 months of baseline visit, b-cell count should be within normal range * prior treatment with any of the following within 3 months of baseline: ctla4-fc ig (abatacept), anti-tnf mab, intravenous ig, plasmapheresis, i.v. or oral cyclophosphamide, i.v. or oral cyclosporine a * screening cbc laboratory values as follows: hemoglobin levels \< 8 g/dl (\< 5 mmol/l), total leukocyte count \< 2,000/µl (2 x 109/l), platelets \< 50,000/µl (50 x 109/l), neutrophil count \< 1,000/µl (1 x 109/l) * pregnant or nursing (lactating) women * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they use a highly effective method of contraception sjs: * sjögren's syndrome overlap syndromes where another autoimmune disease constitutes the primary illness * required regular use of medications known to cause, as a major side effect, dry mouth / eyes other protocol-defined inclusion/exclusion criteria may apply

Keywords: sicca syndrome sjogren syndrome connective tissue disease, mixed mctd sharp syndrome
adaptative radiotherapy to decrease xerostomia in oropharynx carcinoma

Conditions: Oropharynx Cancer

Summary: the phase iii study will include 174 patients with locally advanced oropharynx carcinoma, receiving all arc-imrt (intensity-modulated radiation therapy) (70 gy) with concomitant systemic therapy. two arc-imrt treatment arms will be compared: one "standard" arm based on the use of a single pre-treatment planning and one "experimental" arm (adaptive rt) based on a weekly replanning to spare the salivary glands. the main objective is to increase by 25% the salivary flow (parafilm) 12 months after rt thanks to adaptive rt, while not decreasing local control. the secondary objectives are to increase the salivary flow (scintigraphy), reduce xerostomia, acute and late toxicities (eisbruch questionnaire, mdas-hn, v.4 ctcae), while maintaining local control (stopping rule of the trial if difference\>15%). 174 patients will be included in 6 french centers for 2 years and followed for 2 years. the hpv (human papillomavirus) status will be identified and the tumors frozen. a central imrt qa (quality assurance) will be performed.


Eligibility criteria:
inclusion criteria: 1. locally advanced non-metastatic carcinoma of the oropharynx limited to t3 and t4 (whatever the n) and n2-n3 (whatever the t)(ajcc stage iii-iv) 2. age ≥ 18 years and ≤ 75 years 3. performance status (who ≤ 2) 4. renal, hepatic and cardiovascular functions allowing systemic treatment administration 5. adapted stomatologic care 6. signed informed consent form 7. membership or beneficiary of a national insurance scheme exclusion criteria: 1. both parotids totally included in the target volume 2. stages t1 or t2 with positive node disease n1 3. neoadjuvant chemotherapy 4. exereses of primitive tumor and/or nodes 5. history of other cancer within 5 years (except for basocellular epithelioma and cervical) 6. previous neck radiotherapy 7. platinum salts, 5fluorouracile (5fu) agents or cetuximab chemotherapy considerations 8. unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or sclerodermia)incompatible with study participation 9. patient participating in other therapeutic trial with experimental drug, 30 days before the inclusion. 10. patient already recruited in another biomedical research ( non interventional study is authorized) 11. pregnant or breast feeding patients 12. patient deprived of liberty, under tutorship, guardianship or placed under judicial protection 13. patient is deemed incapable of giving informed consent 14. patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls.

Keywords: adaptative radiotherapy oropharynx carcinoma xerostomia
anti-3-[18f]facbc imaging of parathyroid adenomas

Conditions: Parathyroid Disease

Summary: hyperparathyroidism (excessive production of parathyroid hormone (pth) usually caused by a small growth called an adenoma in the parathyroid glands) is an increasingly significant medical and public health condition. surgery is the only effective management for primary hyperparathyroidism. however; it is sometimes difficult to pinpoint the adenoma, in part because current methods of imaging often fail to identify the parathyroid adenoma in as many as 30% of patients. in reoperative parathyroidectomy for persistent or recurrent hyperparathyroidism, localization plays an even greater role. unfortunately current multiple imaging methods fail to localize 10-15% these of tumors. spect/ct with the radiotracer 99mtc sestamibi has become the standard method for pinpointing the tumor. this, however, is a challenge because the parathyroid glands usually are located close to the thyroid and the radiotracer 99mtc sestamibi concentrates both in thyroid and parathyroid tissue. hence there is a need for a tracer/imaging tool that concentrates in the parathyroid but not in the thyroid. a more sensitive and specific radiotracer/tracking agent would markedly improve the investigators ability to identify parathyroid tumors preoperatively, and thus offer more patients a minimally invasive parathyroidectomy. anti-3-\[18f\]facbc is an amino acid based pet radiotracer which has shown utility in detecting a variety of tumors. in cell culture experiments, anti-3-\[18f\]facbc has shown uptake in parathyroid cells greater than thyroid cells. therefore, the investigators think that this radiotracer may be able to help us identify parathyroid adenomas better than 99mtc sestamibi. the primary aim of this study is to determine if anti-3-\[18f\]facbc pet-ct demonstrates uptake within parathyroid adenomas. 12 patients with a diagnosis of primary hyperparathyroidism will undergo pet-ct using anti-3-\[18f\]facbc in addition to the standard 99mtc sestamibi scanning and other imaging as clinically appropriate such as ultrasound, mri, and/or contrast enhanced ct scanning. since all these patients undergo surgery routinely, the investigators will then compare findings at surgery to those of the anti-3-\[18f\]facbc pet-ct to determine if this radiotracer is worthy of further study in a more comprehensive experiment.


Eligibility criteria:
inclusion criteria: 1. patients must be 18 years of age or older. 2. patients will have biochemical and/or clinical evidence of primary hyperparathyroidism and be a surgical candidate for definitive parathyroid surgery . 3. ability to lie still for pet scanning 4. patients must be able to provide written informed consent exclusion criteria: 1. age less than 18. 2. inability to lie still for pet scanning. 3. cannot provide written informed consent. 4. history of secondary hyperparathyroidism. 5. positive serum or urine pregnancy test within 24 hours of imaging
different limb lengths in gastric bypass surgery

Conditions: Obesity, Morbid; Diabetes Mellitus, Type 2; Hypertension; Dyslipidemias; Sleep Apnea

Summary: obesity and type 2 diabetes mellitus (t2dm) are reaching epidemic proportions in the developed world. in morbidly obese patients only surgical treatment (bariatric operations) leads to a sustained weight loss and relief of co-morbidities in the majority of patients. one of the most frequently performed operations is the laparoscopic proximal roux-en-y gastric bypass (lrygb). there is still lack of knowledge why some patients respond much better than others to an identically performed procedure. therefore, a number of variations of this operation have been introduced over the past 50 years. increasing the length of small bowel being bypassed has the potential to improve the effect of the operation but buries the risk of nutrient deficiencies. the metabolic effect of lrygb occurs, in part, independently of weight loss. the mechanisms underlying metabolic improvement through metabolic surgery are not yet fully understood.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * patients with bmi of 35 kg/m2 or higher who comply with the regulatory rules for bariatric surgery in switzerland exclusion criteria: * general contraindications to kind of surgery * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders etc. of the participant * participation in another study * age \ 65 years * bmi \> 60 kg/m2 * height \< 145 cm * cl length of \< 180 cm as measured intraoperatively * asa physical status classification \> iii * inflammatory bowel disease

Keywords: roux-en-y gastric bypass biliopancreatic limb length
serum neurofilament light (nfl) as a marker for brain injury in individuals undergoing chimeric antigen receptor-modified t therapy

Conditions: Neurotoxicity

Summary: the investigators propose that immune effector cell-associated neurotoxicity syndrome (icans) is predicated upon the early loss of blood brain barrier (bbb) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. glial overstimulation leads to neuroinflammation, synaptic dysfunction, and ultimately neuronal injury.


Eligibility criteria:
inclusion criteria: * clinically scheduled to undergo treatment with tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, or lisocabtagene maraleucel. * at least 18 years of age. * able and willing to undergo study testing (blood draws, lumbar punctures, neuro-psychiatric testing, and neuroimaging with mri) * participants of childbearing potential without documented history of menopause or hysterectomy who choose to participate must not be pregnant at screening and must agree to avoid becoming pregnant prior to scanning. * able to understand and willing to sign an irb-approved written informed consent document. exclusion criteria: * has any condition that, in the investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants unable to lie flat for the duration of the mri scan). * contraindications to mr imaging (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. patients with pacemakers may only be scanned if approved by ccir staff and radiology review. * severe claustrophobia. * history of multiple sclerosis, parkinson's disease, dementia (including alzheimer's disease, frontotemporal dementia, and pick's disease), or motor neuron disease including amyotrophic lateral sclerosis (als) * for the lumbar puncture associated with the study only: contraindications to lumbar puncture (e.g. platelets \ 1.5, evidence of midline shift on imaging, presence of local infection at lp site, history of baclofen pump, history of significant spinal surgery/hardware which would preclude safe bedside lumbar puncture). if a contraindication to lumbar puncture develops while on study, patient may remain on study but will be barred from a lumbar puncture until that contraindication resolves. * pregnant * enrolled in an interventional study of a drug targeting neurotoxicity